# Diagnosis of Diabetes Mellitus

## Diagnostic Criteria (ADA 2024)

### Fasting Plasma Glucose (FPG)
- **Diabetes**: ≥126 mg/dL (7.0 mmol/L)
- **Prediabetes (IFG)**: 100-125 mg/dL (5.6-6.9 mmol/L)
- **Normal**: <100 mg/dL (5.6 mmol/L)
- **Reproducibility**: CV <5% in good labs

### 2-hour Plasma Glucose (2hPG) during Oral Glucose Tolerance Test (OGTT)
- **Diabetes**: ≥200 mg/dL (11.1 mmol/L)
- **Prediabetes (IGT)**: 140-199 mg/dL (7.8-11.0 mmol/L)
- **Normal**: <140 mg/dL (7.8 mmol/L)
- **Standard test**: 75g glucose load

### Glycated Hemoglobin (HbA1c)
- **Diabetes**: ≥6.5% (48 mmol/mol)
- **Prediabetes**: 5.7-6.4% (39-46 mmol/mol)
- **Normal**: <5.7% (<39 mmol/mol)
- **Point-of-care**: Calibrated against NGSP standard

## Clinical Diagnosis in Symptomatic Patients

### Classic Symptoms Plus Random Glucose
- **Symptoms**: Polyuria, polydipsia, unexplained weight loss
- **Random plasma glucose**: ≥200 mg/dL + symptoms = diabetes
- **No need for confirmatory testing** unless borderline results
- **Emergent situations**: Immediate treatment initiation

### Symptoms of Hyperglycemia
- **Polyuria**: >3L urine/day
- **Polydipsia**: Excessive thirst
- **Polyphagia**: Increased hunger despite eating
- **Fatigue**: Unexplained tiredness
- **Weight loss**: >5% body weight in 1-2 months
- **Blurred vision**: Fluctuating vision
- **Slow wound healing**: Cuts take longer to heal

## Confirmatory Testing Strategy

### When to Use Multiple Tests
- **Asymptomatic patients**: Require confirmatory testing
- **Borderline results**: Repeat or second method
- **High-risk individuals**: Two abnormal results for diagnosis
- **Uncertain diagnosis**: Further metabolic testing

### Repeat Testing Schedule
- **If initial result normal**: Repeat annually based on risk
- **If prediabetes**: Repeat every 1-3 years
- **If borderline**: Confirm within 3-6 months
- **If factors interfere**: Recheck after resolving factors

## Laboratory Testing Methodology

### Specimen Collection and Handling
- **Blood sample**: Venous EDTA for HbA1c, serum for glucose
- **Fasting**: No caloric intake for ≥8 hours
- **OGTT procedure**:
  - 75g glucose in 250-300 mL water
  - Drink within 5 minutes
  - Timing: 0 and 120 minutes
- **Storage**: Store at 4°C if immediate analysis not possible

### Analytical Methods

#### Glucose Measurement
- **Hexokinase method**: Gold standard for plasma glucose
- **Glucose oxidase**: More interference-prone
- **Point-of-care glucometers**: ±15% accuracy acceptable
- **Whole blood vs plasma**: Plasma = whole blood + 14%

#### HbA1c Measurement
- **HPLC**: Most accurate, separates HbA1c from hemoglobin variants
- **Immunoassay**: Less expensive, affected by hemoglobinopathies
- **Capillary electrophoresis**: Higher resolution
- **NGSP certification**: Required for clinical use

### Assay Performance
- **Precision**: Within-run CV <2%, total CV <5%
- **Accuracy**: Bias <5% from reference method
- **Interferents**: Hemolysis, lipemia can affect results
- **QC measures**: Daily controls, external quality assurance

## Screening Recommendations

### Target Groups for Screening
- **High risk adults**: BMI ≥25 kg/m² + one risk factor
- **Age ≥45 years**: Universal screening
- **Overweight children**: BMI ≥85th percentile + risk factors
- **Pregnant women**: Universal GDM screening at 24-28 weeks

### Risk Factors for Targeted Screening
- **Family history**: First-degree relative with diabetes
- **Race/ethnicity**: South Asian, African American, Hispanic
- **Gestational history**: Previous GDM, macrosomia
- **Metabolic syndrome**: Hypertension, dyslipidemia, obesity
- **Polycystic ovary syndrome**
- **Physical inactivity**: Sedentary lifestyle

### Screening Tests
- **HbA1c**: Preferred first-line screening test
- **FPG**: Alternative when HbA1c not available
- **OGTT**: For diagnosis when FPG/HbA1c equivocal
- **Point-of-care testing**: Rapid screening in community settings

## Special Diagnostic Situations

### Pregnancy
- **GDM diagnosis**: IADPSG 2010 criteria
- **Carpenter-Coustan**: Traditional criteria (higher thresholds)
- **Timing**: 24-28 weeks or earlier if risk factors
- **Postpartum**: Screen for diabetes at 6-12 weeks

### Children and Adolescents
- **Symptoms + random glucose**: Diagnosis confirmed
- **Asymptomatic**: Two abnormal tests or single + confirmatory
- **Behavior changes**: May represent subtle symptoms
- **Pubertal status**: Insulin resistance affects results

### Hospitalized Patients
- **Stress hyperglycemia**: Transient elevations
- **Critically ill**: Use OGTT for accurate diagnosis
- **Steroid use**: May cause temporary elevation
- **Parenteral nutrition**: Affects insulin sensitivity

### Elderly Patients
- **Low specificity of HbA1c**: Anemia, renal disease
- **FPG preferred**: Fewer confounders in elderly
- **Medication effects**: Multiple comorbidities
- **Functional status**: Consider frailty in decision-making

### Hemoglobinopathies
- **Sickle cell disease**: Spurious HbA1c elevations
- **Thalassemia**: Variable interference
- **Iron deficiency**: Mild increase in HbA1c
- **Alternative**: Fructosamine or 1,5-anhydroglucitol

## Differential Diagnosis

### Differentiating from Other Hyperglycemia Causes
- **Steroid therapy**: Reversible upon discontinuation
- **Pancreatitis**: Associated symptoms, amylase elevation
- **Endocrine disorders**: Acromegaly, Cushing's, pheochromocytoma
- **Drug-induced**: Protease inhibitors, antipsychotics, thiazides
- **Malnutrition**: Associated features, low BMI

### Differentiating Diabetes Types
- **T1DM vs T2DM**: Antibodies, C-peptide, ketoacidosis risk
- **MODY**: Family history, younger onset, preserved C-peptide
- **Secondary diabetes**: Pancreatic disease, endocrinopathy
- **Genetic testing**: For monogenic forms

## Biochemical Markers for Diagnosis

### Antibodies (for T1DM discrimination)
- **GAD antibodies**: Most common, persist for years
- **IA-2 antibodies**: Specific for β-cells
- **Insulin autoantibodies**: Present at onset
- **ZnT8 antibodies**: Recent addition, improve specificity

### C-Peptide Measurement
- **T1DM**: Low or undetectable (<0.2 ng/mL)
- **T2DM**: Normal or elevated (often >1.0 ng/mL)
- **Factitious hypoglycemia**: Undetectable C-peptide
- **Assessment of β-cell function**

### Other Biomarkers
- **Proinsulin**: Elevated in T2DM, indicates β-cell dysfunction
- **1,5-Anhydroglucitol**: Reflects recent glycemic control
- **Fructosamine**: 2-3 week glycemic control indicator
- **Incretins**: GIP, GLP-1 levels may be abnormal

## Complications Screening at Diagnosis

### Required Investigations
- **Lipid profile**: Total cholesterol, HDL, LDL, triglycerides
- **Kidney function**: Serum creatinine, eGFR, albuminuria
- **Liver function**: ALT, AST (NAFLD common)
- **Cardiovascular risk**: ECG if indicated
- **Retinopathy**: Dilated eye examination
- **Neuropathy**: Foot examination, vibration testing

### Timing
- **At diagnosis**: Comprehensive evaluation
- **Annual screening**: Complications surveillance
- **More frequent**: If uncontrolled or high-risk features
- **Pre-conception**: Detailed assessment

## Quality Assurance in Diagnosis

### Laboratory Quality Control
- **Calibration**: Regular standardization against reference methods
- **Quality assessment**: Participation in external programs
- **Staff training**: Competency testing for technique
- **Equipment maintenance**: Regular calibration and validation

### Clinical Decision Support
- **Diagnostic algorithms**: Standardized approaches
- **Risk stratification**: Family history, symptoms correlation
- **Follow-up planning**: Based on diagnosis and risk
- **Patient education**: During diagnosis process

## Learning Objectives
- Apply ADA diagnostic criteria for diabetes mellitus
- Select appropriate diagnostic tests based on clinical situation
- Interpret laboratory results and confirm diagnosis
- Distinguish between diabetes types using biochemical markers
- Perform comprehensive screening for diabetes complications
- Ensure quality assurance in diagnostic process
